These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 8303305)

  • 21. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
    Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
    Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
    Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
    Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
    Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapies to improve tumor immunotherapy.
    Begley J; Ribas A
    Clin Cancer Res; 2008 Jul; 14(14):4385-91. PubMed ID: 18628452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapeutic strategies employing RNA interference technology for the control of cancers.
    Mao CP; Hung CF; Wu TC
    J Biomed Sci; 2007 Jan; 14(1):15-29. PubMed ID: 17103251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local and systemic antitumor response after combined therapy of mouse metastatic tumors with tumor cells expressing IFN-alpha and HSVtk: perspectives for the generation of cancer vaccines.
    Santodonato L; D'Agostino G; Santini SM; Carlei D; Musiani P; Modesti A; Signorelli P; Belardelli F; Ferrantini M
    Gene Ther; 1997 Nov; 4(11):1246-55. PubMed ID: 9425449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of established tumors in mice by intratumoral injection of an adenovirus vector harboring the human IL-2 cDNA: induction of CD8(+) T-cell immunity and NK activity.
    Slos P; De Meyer M; Leroy P; Rousseau C; Acres B
    Cancer Gene Ther; 2001 May; 8(5):321-32. PubMed ID: 11477452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor vaccine: current trends in antigen specific immunotherapy.
    Baral R
    Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boosting the immune response: an alternative combination therapy for cancer patients.
    Thyphronitis G; Koutsilieris M
    Anticancer Res; 2004; 24(4):2443-53. PubMed ID: 15330197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
    Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
    Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy.
    Schreurs MW; Eggert AA; Punt CJ; Figdor CG; Adema GJ
    Crit Rev Oncog; 2000; 11(1):1-17. PubMed ID: 10795625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adoptive immunotherapy of cancer: accomplishments and prospects.
    Rosenberg SA
    Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth.
    Campbell I; Moyana T; Carlsen S; Zheng C; Xiang J
    Cancer Gene Ther; 2000 Jan; 7(1):37-44. PubMed ID: 10678354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In situ cytokine gene transfection using vaccinia virus vectors.
    Lattime EC; Lee SS; Eisenlohr LC; Mastrangelo MJ
    Semin Oncol; 1996 Feb; 23(1):88-100. PubMed ID: 8607035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.